{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:36:43Z","timestamp":1781879803907,"version":"3.54.5"},"reference-count":76,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007771","name":"Medical University of Silesia","doi-asserted-by":"publisher","award":["KNW-1-204\/N\/8\/0"],"award-info":[{"award-number":["KNW-1-204\/N\/8\/0"]}],"id":[{"id":"10.13039\/100007771","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Introduction: Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating disease of the central nervous system with a highly heterogeneous clinical course. Early identification of patients at risk of aggressive disease progression is crucial for optimizing therapeutic strategies, including eligibility for highly effective treatments. Objective: The aim of this review was to synthesize current data on prognostic factors in multiple sclerosis, with particular emphasis on their significance in the early stages of the disease and potential clinical implications. Methods: A narrative systematic review of the literature was conducted, including observational studies, cohort studies, meta-analyses, and systematic reviews on the natural course of MS, prognostic factors, and clinical, neuroimaging, and laboratory biomarkers. We comprehensively reviewed PubMed and Scopus databases, focusing on English-language publications. Study selection prioritized longitudinal studies and meta-analyses with clear outcome definitions and sufficient follow-up. Formal quality scoring was not applied due to the narrative design of the review. Results: Key adverse prognostic factors include older age at onset, polysymptomatic onset, high relapse activity in the first years, incomplete remission after relapses, and the primary progressive form. Magnetic resonance imaging features, including the number and location of T2 lesions, contrast activity, the presence of spinal cord lesions, PRLs and SELs, and severe brain atrophy, also have significant predictive value. Increasing importance is being attached to laboratory biomarkers, such as oligoclonal bands, light neurofilaments, free kappa light chains, and GFAP. Conclusions: An integrated assessment of clinical, neuroimaging, and laboratory factors enables more effective risk stratification in patients with newly diagnosed MS. Early identification of an unfavorable prognostic profile may provide a basis for individualizing treatment and considering the use of highly effective therapies early in the course of the disease.<\/jats:p>","DOI":"10.3390\/medicina62030475","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T16:06:59Z","timestamp":1772467619000},"page":"475","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Early Prognostic Factors in Multiple Sclerosis: Clinical and Therapeutic Implications"],"prefix":"10.3390","volume":"62","author":[{"given":"Katarzyna","family":"Maciejowska-Szyd\u0142o","sequence":"first","affiliation":[{"name":"Department of Neurology, Faculty of Health Sciences in Katowice, Medical University of Silesia, 40-635 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7787-5660","authenticated-orcid":false,"given":"Przemys\u0142aw","family":"Puz","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Health Sciences in Katowice, Medical University of Silesia, 40-635 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ene.13819","article-title":"Multiple Sclerosis\u2014A Review","volume":"26","author":"Dobson","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0140-6736(23)01473-3","article-title":"Multiple Sclerosis","volume":"403","author":"Jakimovski","year":"2024","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/WCO.0000000000001268","article-title":"Shifting Our Attention Earlier in the Multiple Sclerosis Disease Course","volume":"37","author":"Epstein","year":"2024","journal-title":"Curr. Opin. Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00415-023-11969-8","article-title":"Multiple Sclerosis: Time for Early Treatment with High-Efficacy Drugs","volume":"271","author":"Selmaj","year":"2024","journal-title":"J. Neurol."},{"key":"ref_5","first-page":"e1280","article-title":"Association of Very Early Treatment Initiation with the Risk of Long-Term Disability in Patients with a First Demyelinating Event","volume":"101","author":"Tur","year":"2023","journal-title":"Neurology"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Van Wijmeersch, B., Hartung, H.-P., Vermersch, P., Pugliatti, M., Pozzilli, C., Grigoriadis, N., Alkhawajah, M., Airas, L., Linker, R., and Oreja-Guevara, C. (2022). Using Personalized Prognosis in the Treatment of Relapsing Multiple Sclerosis: A Practical Guide. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.991291"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Prosperini, L., Ruggieri, S., Haggiag, S., Tortorella, C., Pozzilli, C., and Gasperini, C. (2021). Prognostic Accuracy of NEDA-3 in Long-Term Outcomes of Multiple Sclerosis. Neurol. Neuroimmunol. Neuroinflamm., 8.","DOI":"10.1212\/NXI.0000000000001059"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/brain\/awl007","article-title":"Natural History of Multiple Sclerosis: A Unifying Concept","volume":"129","author":"Confavreux","year":"2006","journal-title":"Brain"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Reeve, K., On, B.I., Havla, J., Burns, J., Gosteli-Peter, M.A., Alabsawi, A., Alayash, Z., G\u00f6tschi, A., Seibold, H., and Mansmann, U. (2023). Prognostic Models for Predicting Clinical Disease Progression, Worsening and Activity in People with Multiple Sclerosis. Cochrane Database Syst. Rev., 9.","DOI":"10.1002\/14651858.CD013606.pub2"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/brain\/112.1.133","article-title":"The Natural History of Multiple Sclerosis: A Geographically Based Study. I. Clinical Course and Disability","volume":"112","author":"Weinshenker","year":"1989","journal-title":"Brain"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.msard.2019.01.039","article-title":"Highly Active Multiple Sclerosis: An Update","volume":"30","author":"Zarco","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/1352458508088625","article-title":"Defining the Natural History of MS: The Need for Complete Data and Rigorous Definitions","volume":"14","author":"Confavreux","year":"2008","journal-title":"Mult. Scler."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1136\/jnnp.50.5.523","article-title":"Survival Pattern and Cause of Death in Patients with Multiple Sclerosis: Results from an Epidemiological Survey in North East Scotland","volume":"50","author":"Phadke","year":"1987","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1136\/jnnp.55.5.341","article-title":"The Natural History of Multiple Sclerosis: A Regional Study with Some Longitudinal Data","volume":"55","author":"Miller","year":"1992","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1600-0404.1990.tb04483.x","article-title":"Incidence of MS during Two Fifteen-Year Periods in the Gothenburg Region of Sweden","volume":"82","author":"Svenningsson","year":"1990","journal-title":"Acta Neurol. Scand."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1093\/brain\/awq118","article-title":"The Natural History of Multiple Sclerosis: A Geographically Based Study 10: Relapses and Long-Term Disability","volume":"133","author":"Scalfari","year":"2010","journal-title":"Brain"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1177\/1352458507084264","article-title":"Natural History of Secondary-Progressive Multiple Sclerosis","volume":"14","author":"Tremlett","year":"2008","journal-title":"Mult. Scler."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0022-510X(99)00143-4","article-title":"A Prospective Study on the Natural History of Multiple Sclerosis: Clues to the Conduct and Interpretation of Clinical Trials","volume":"168","author":"Amato","year":"1999","journal-title":"J. Neurol. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1093\/brain\/awv105","article-title":"Defining High, Medium and Low Impact Prognostic Factors for Developing Multiple Sclerosis","volume":"138","author":"Tintore","year":"2015","journal-title":"Brain"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1093\/brain\/awt281","article-title":"Sex as a Determinant of Relapse Incidence and Progressive Course of Multiple Sclerosis","volume":"136","author":"Kalincik","year":"2013","journal-title":"Brain"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"17562864241237853","DOI":"10.1177\/17562864241237853","article-title":"Sex Differences in Multiple Sclerosis Relapse Presentation and Outcome: A Retrospective, Monocentric Study of 134 Relapse Events","volume":"17","author":"Veselaj","year":"2024","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1177\/1352458520974366","article-title":"Transition to Secondary Progression in Relapsing-Onset Multiple Sclerosis: Definitions and Risk Factors","volume":"27","author":"Iaffaldano","year":"2021","journal-title":"Mult. Scler."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/brain\/awh714","article-title":"Age at Disability Milestones in Multiple Sclerosis","volume":"129","author":"Confavreux","year":"2006","journal-title":"Brain"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1136\/jnnp-2022-329353","article-title":"Younger Age at Multiple Sclerosis Onset Is Associated with Worse Outcomes at Age 50","volume":"93","author":"Bose","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1177\/1352458516679894","article-title":"Hispanic Americans and African Americans with Multiple Sclerosis Have More Severe Disease Course than Caucasian Americans","volume":"23","author":"Ventura","year":"2017","journal-title":"Mult. Scler."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1212\/01.WNL.0000145762.60562.5D","article-title":"Clinical Characteristics of African Americans vs Caucasian Americans with Multiple Sclerosis","volume":"63","author":"Cree","year":"2004","journal-title":"Neurology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1191\/1352458503ms909oa","article-title":"Multiple Sclerosis Characteristics in African American Patients in the New York State Multiple Sclerosis Consortium","volume":"9","author":"Jacobs","year":"2003","journal-title":"Mult. Scler."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.msard.2016.03.011","article-title":"Prognostic Factors Associated with Long-Term Disability and Secondary Progression in Patients with Multiple Sclerosis","volume":"8","author":"Vasconcelos","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1212\/WNL.0b013e3181d6b125","article-title":"Vascular Comorbidity Is Associated with More Rapid Disability Progression in Multiple Sclerosis","volume":"74","author":"Marrie","year":"2010","journal-title":"Neurology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1177\/1352458512436596","article-title":"High Body Mass Index before Age 20 Is Associated with Increased Risk for Multiple Sclerosis in Both Men and Women","volume":"18","author":"Olsson","year":"2012","journal-title":"Mult. Scler."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/ane.12916","article-title":"Smoking and Worsening Disability in Multiple Sclerosis: A Meta-Analysis","volume":"138","author":"Heydarpour","year":"2018","journal-title":"Acta Neurol. Scand."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.msard.2019.01.045","article-title":"Prognostic Factors of Disability in Relapsing Remitting Multiple Sclerosis","volume":"30","author":"Briggs","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"106667","DOI":"10.1016\/j.msard.2025.106667","article-title":"Prediction of Long-Term Outcome in Multiple Sclerosis: A Systematic Review","volume":"103","author":"Mrabet","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/0895-4356(88)90041-8","article-title":"Prognostic Factors for Life Expectancy in Multiple Sclerosis Analysed by Cox-Models","volume":"41","author":"Riise","year":"1988","journal-title":"J. Clin. Epidemiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1212\/WNL.0000000000002830","article-title":"Assessing Response to Interferon-\u03b2 in a Multicenter Dataset of Patients with MS","volume":"87","author":"Sormani","year":"2016","journal-title":"Neurology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1191\/1352458503ms914oa","article-title":"Long-Term Follow up of Patients with Clinically Isolated Syndromes, Relapsing-Remitting and Secondary Progressive Multiple Sclerosis","volume":"9","author":"Eriksson","year":"2003","journal-title":"Mult. Scler."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jamaneurol.2022.4655","article-title":"Association of Early Progression Independent of Relapse Activity with Long-Term Disability After a First Demyelinating Event in Multiple Sclerosis","volume":"80","author":"Tur","year":"2023","journal-title":"JAMA Neurol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1093\/brain\/114.2.1045","article-title":"The Natural History of Multiple Sclerosis: A Geographically Based Study. 3. Multivariate Analysis of Predictive Factors and Models of Outcome","volume":"114","author":"Weinshenker","year":"1991","journal-title":"Brain"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1054\/jocn.1998.0107","article-title":"Multiple Sclerosis in Australia: Prognostic Factors","volume":"7","author":"Hammond","year":"2000","journal-title":"J. Clin. Neurosci."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Poretto, V., Endrizzi, W., Betti, M., Bovo, S., Bellinvia, A., Ragni, F., Lapucci, C., Moroni, M., Marangoni, S., and Portaccio, E. (2025). Machine Learning Analysis Applied to Prediction of Early Progression Independent of Relapse Activity in Multiple Sclerosis Patients. Eur. J. Neurol., 32.","DOI":"10.1111\/ene.70417"},{"key":"ref_41","first-page":"979","article-title":"Prognostic Factors for Disease Activity in Newly Diagnosed Teriflunomide-Treated Patients with Multiple Sclerosis: A Nationwide Danish Study","volume":"95","author":"Mahler","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s10072-026-08876-x","article-title":"Refining Predictors of Long-Term NEDA-3 Status in Relapsing-Remitting Multiple Sclerosis: Insights from Real-World Data","volume":"47","author":"Guerra","year":"2026","journal-title":"Neurol. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Lomer, N.B., Asalemi, K.A., Saberi, A., and Sarlak, K. (2024). Predictors of Multiple Sclerosis Progression: A Systematic Review of Conventional Magnetic Resonance Imaging Studies. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0300415"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/brain\/awm329","article-title":"Disability and T2 MRI Lesions: A 20-Year Follow-up of Patients with Relapse Onset of Multiple Sclerosis","volume":"131","author":"Fisniku","year":"2008","journal-title":"Brain"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1212\/WNL.0b013e3181feb26f","article-title":"Brainstem Lesions in Clinically Isolated Syndromes","volume":"75","author":"Tintore","year":"2010","journal-title":"Neurology"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Andelova, M., Vodehnalova, K., Krasensky, J., Hardubejova, E., Hrnciarova, T., Srpova, B., Uher, T., Menkyova, I., Stastna, D., and Friedova, L. (2022). Brainstem Lesions Are Associated with Diffuse Spinal Cord Involvement in Early Multiple Sclerosis. BMC Neurol., 22.","DOI":"10.1186\/s12883-022-02778-z"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1474-4422(13)70103-0","article-title":"MRI Lesions as a Surrogate for Relapses in Multiple Sclerosis: A Meta-Analysis of Randomised Trials","volume":"12","author":"Sormani","year":"2013","journal-title":"Lancet Neurol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1001\/jamaneurol.2019.2399","article-title":"Association of Chronic Active Multiple Sclerosis Lesions with Disability In Vivo","volume":"76","author":"Absinta","year":"2019","journal-title":"JAMA Neurol."},{"key":"ref_49","first-page":"1584","article-title":"Patterning Chronic Active Demyelination in Slowly Expanding\/Evolving White Matter MS Lesions","volume":"41","author":"Elliott","year":"2020","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1177\/13524585241229956","article-title":"Paramagnetic Rim Lesions Predict Greater Long-Term Relapse Rates and Clinical Progression over 10 Years","volume":"30","author":"Reeves","year":"2024","journal-title":"Mult. Scler."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/jmri.28847","article-title":"Evaluation of the Blood-Brain Barrier, Demyelination, and Neurodegeneration in Paramagnetic Rim Lesions in Multiple Sclerosis on 7 Tesla MRI","volume":"59","author":"Choi","year":"2024","journal-title":"J. Magn. Reson. Imaging"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1212\/01.wnl.0000173061.12776.1f","article-title":"Long-Term Clinical Outcome of Primary Progressive MS: Predictive Value of Clinical and MRI Data","volume":"65","author":"Ingle","year":"2005","journal-title":"Neurology"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Gajewski, B., Siger, M., Karli\u0144ska, I., Bednarski, I.A., \u015awiderek-Matysiak, M., and Stasio\u0142ek, M. (2025). Brain Atrophy and Cognitive Impairment in Primary and Secondary Progressive Multiple Sclerosis Cohort-Similar Progressive MS Phenotype. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26178523"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Preziosa, P., Pagani, E., Meani, A., Moiola, L., Rodegher, M., Filippi, M., and Rocca, M.A. (2022). Slowly Expanding Lesions Predict 9-Year Multiple Sclerosis Disease Progression. Neurol. Neuroimmunol. Neuroinflamm., 9.","DOI":"10.1212\/NXI.0000000000001139"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/jnnp-2012-304695","article-title":"Cerebrospinal Fluid Oligoclonal Bands in Multiple Sclerosis and Clinically Isolated Syndromes: A Meta-Analysis of Prevalence, Prognosis and Effect of Latitude","volume":"84","author":"Dobson","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Coll-Martinez, C., Quintana, E., Salavedra-Pont, J., Bux\u00f3, M., Gonz\u00e1lez-Del-Rio, M., G\u00f3mez, I., Mu\u00f1oz-San Mart\u00edn, M., Villar, L.M., \u00c1lvarez-Bravo, G., and Robles-Cede\u00f1o, R. (2021). Assessing the Presence of Oligoclonal IgM Bands as a Prognostic Biomarker of Cognitive Decline in the Early Stages of Multiple Sclerosis. Brain Behav., 11.","DOI":"10.1002\/brb3.2405"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Monreal, E., Sainz de la Maza, S., Costa-Frossard, L., Walo-Delgado, P., Zamora, J., Fern\u00e1ndez-Velasco, J.I., Villarrubia, N., Espi\u00f1o, M., Lourido, D., and Lapuente, P. (2021). Predicting Aggressive Multiple Sclerosis with Intrathecal IgM Synthesis Among Patients With a Clinically Isolated Syndrome. Neurol. Neuroimmunol. Neuroinflamm., 8.","DOI":"10.1212\/NXI.0000000000001047"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamaneurol.2022.5250","article-title":"Serum Glial Fibrillary Acidic Protein Compared with Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis","volume":"80","author":"Meier","year":"2023","journal-title":"JAMA Neurol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"105747","DOI":"10.1016\/j.msard.2024.105747","article-title":"Serum NfL and GFAP Are Weak Predictors of Long-Term Multiple Sclerosis Prognosis: A 6-Year Follow-Up","volume":"89","author":"Ayrignac","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"14987","DOI":"10.1038\/s41598-021-94423-x","article-title":"Cerebrospinal Fluid Oligoclonal Immunoglobulin Gamma Bands and Long-Term Disability Progression in Multiple Sclerosis: A Retrospective Cohort Study","volume":"11","author":"Karrenbauer","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4800","DOI":"10.1007\/s00415-023-11817-9","article-title":"Intrathecal Kappa Free Light Chain Synthesis Is Associated with Worse Prognosis in Relapsing-Remitting Multiple Sclerosis","volume":"270","author":"Rosenstein","year":"2023","journal-title":"J. Neurol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Virgilio, E., Ciampana, V., Puricelli, C., Naldi, P., Bianchi, A., Dianzani, U., Vecchio, D., and Comi, C. (2025). Biomarkers of Intrathecal Synthesis May Be Associated with Cognitive Impairment at MS Diagnosis. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26020826"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Barro, C., Healy, B.C., Liu, Y., Saxena, S., Paul, A., Polgar-Turcsanyi, M., Guttmann, C.R.G., Bakshi, R., Kropshofer, H., and Weiner, H.L. (2023). Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients with Progressive Multiple Sclerosis. Neurol. Neuroimmunol. Neuroinflamm., 10.","DOI":"10.1212\/NXI.0000000000200052"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","article-title":"Serum Neurofilament Light Chain for Individual Prognostication of Disease Activity in People with Multiple Sclerosis: A Retrospective Modelling and Validation Study","volume":"21","author":"Benkert","year":"2022","journal-title":"Lancet Neurol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S1474-4422(19)30151-6","article-title":"Early Highly Effective versus Escalation Treatment Approaches in Relapsing Multiple Sclerosis","volume":"18","author":"Ontaneda","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"17562864211019574","DOI":"10.1177\/17562864211019574","article-title":"Long-Term Disability Trajectories in Relapsing Multiple Sclerosis Patients Treated with Early Intensive or Escalation Treatment Strategies","volume":"14","author":"Iaffaldano","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ncl.2023.06.004","article-title":"Highly Effective Therapy Versus Escalation Approaches in Early Multiple Sclerosis: What Is the Future of Multiple Sclerosis Treatment?","volume":"42","author":"Mowry","year":"2024","journal-title":"Neurol. Clin."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1177\/13524585241258692","article-title":"Benefits of Early Highly Effective versus Escalation Treatment Strategies in Relapsing Multiple Sclerosis Estimated Using a Treatment-Sequence Model","volume":"30","author":"Smets","year":"2024","journal-title":"Mult. Scler."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/acn3.70131","article-title":"Early Intensive Versus Escalation Approach: Ten-Year Impact on Disability in Relapsing Multiple Sclerosis","volume":"12","author":"Iaffaldano","year":"2025","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1007\/s00415-022-11193-w","article-title":"Early Use of High-Efficacy Disease-modifying Therapies Makes the Difference in People with Multiple Sclerosis: An Expert Opinion","volume":"269","author":"Filippi","year":"2022","journal-title":"J. Neurol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1212\/WNL.0000000000207754","article-title":"Early Treatment for Multiple Sclerosis: Time Is Brain","volume":"101","author":"Longbrake","year":"2023","journal-title":"Neurology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"041503","DOI":"10.1063\/5.0011697","article-title":"Artificial Intelligence for Brain Diseases: A Systematic Review","volume":"4","author":"Segato","year":"2020","journal-title":"APL Bioeng."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Tayyab, M., Metz, L.M., Li, D.K.B., Kolind, S., Carruthers, R., Traboulsee, A., and Tam, R.C. (2023). Accounting for Uncertainty in Training Data to Improve Machine Learning Performance in Predicting New Disease Activity in Early Multiple Sclerosis. Front. Neurol., 14.","DOI":"10.3389\/fneur.2023.1165267"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"105614","DOI":"10.1016\/j.msard.2024.105614","article-title":"Predicting the Conversion from Clinically Isolated Syndrome to Multiple Sclerosis: An Explainable Machine Learning Approach","volume":"86","author":"Rasouli","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s42979-021-00592-x","article-title":"Machine Learning: Algorithms, Real-World Applications and Research Directions","volume":"2","author":"Sarker","year":"2021","journal-title":"SN Comput. Sci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"6543","DOI":"10.1007\/s00415-024-12651-3","article-title":"Predicting Multiple Sclerosis Disease Progression and Outcomes with Machine Learning and MRI-Based Biomarkers: A Review","volume":"271","author":"Yousef","year":"2024","journal-title":"J. Neurol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/3\/475\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T16:48:18Z","timestamp":1772470098000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/3\/475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":76,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["medicina62030475"],"URL":"https:\/\/doi.org\/10.3390\/medicina62030475","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]}}}